170 related articles for article (PubMed ID: 20118145)
1. Golimumab: a tumor necrosis factor alpha inhibitor for the treatment of rheumatoid arthritis.
McCluggage LK; Scholtz JM
Ann Pharmacother; 2010 Jan; 44(1):135-44. PubMed ID: 20118145
[TBL] [Abstract][Full Text] [Related]
2. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
Boyce EG; Halilovic J; Stan-Ugbene O
Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
[TBL] [Abstract][Full Text] [Related]
3. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis.
Tanaka Y; Senoo A; Fujii H; Baker D
Expert Opin Drug Metab Toxicol; 2016; 12(3):319-26. PubMed ID: 26811250
[TBL] [Abstract][Full Text] [Related]
5. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study.
Smolen JS; Kay J; Doyle M; Landewé R; Matteson EL; Gaylis N; Wollenhaupt J; Murphy FT; Xu S; Zhou Y; Hsia EC
Arthritis Res Ther; 2015 Jan; 17(1):14. PubMed ID: 25627338
[TBL] [Abstract][Full Text] [Related]
6. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Oldfield V; Plosker GL
BioDrugs; 2009; 23(2):125-35. PubMed ID: 19489653
[TBL] [Abstract][Full Text] [Related]
7. Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Campas-Moya C
Drugs Today (Barc); 2010 Jan; 46(1):13-22. PubMed ID: 20200692
[TBL] [Abstract][Full Text] [Related]
8. Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Voulgari PV
Expert Rev Clin Immunol; 2010 Sep; 6(5):721-33. PubMed ID: 20828280
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab: an interleukin-6 receptor inhibitor for the treatment of rheumatoid arthritis.
Plushner SL
Ann Pharmacother; 2008 Nov; 42(11):1660-8. PubMed ID: 18957621
[TBL] [Abstract][Full Text] [Related]
11. Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs: a NICE single technology appraisal.
Tosh J; Archer R; Davis S; Stevenson M; Stevens JW
Pharmacoeconomics; 2013 Aug; 31(8):653-61. PubMed ID: 23576019
[TBL] [Abstract][Full Text] [Related]
12. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
Kremer J; Ritchlin C; Mendelsohn A; Baker D; Kim L; Xu Z; Han J; Taylor P
Arthritis Rheum; 2010 Apr; 62(4):917-28. PubMed ID: 20131276
[TBL] [Abstract][Full Text] [Related]
13. Golimumab for rheumatoid arthritis.
Singh JA; Noorbaloochi S; Singh G
Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD008341. PubMed ID: 20091667
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and adverse effects of golimumab in the treatment of rheumatoid arthritis.
Chovel-Sella A; Karplus R; Sella T; Amital H
Isr Med Assoc J; 2012 Jun; 14(6):390-4. PubMed ID: 22891404
[TBL] [Abstract][Full Text] [Related]
15. Novel TNF antagonists for the treatment of rheumatoid arthritis.
Statkute L; Ruderman EM
Expert Opin Investig Drugs; 2010 Jan; 19(1):105-15. PubMed ID: 20001558
[TBL] [Abstract][Full Text] [Related]
16. Golimumab, the newest TNF-α blocker, comes of age.
Papagoras C; Voulgari PV; Drosos AA
Clin Exp Rheumatol; 2015; 33(4):570-7. PubMed ID: 25602858
[TBL] [Abstract][Full Text] [Related]
17. Golimumab as the first monthly subcutaneous fully human anti-TNF-alpha antibody in the treatment of inflammatory arthropathies.
Hutas G
Immunotherapy; 2010 Jul; 2(4):453-60. PubMed ID: 20635999
[TBL] [Abstract][Full Text] [Related]
18. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160.
Smolen JS; Kay J; Landewé RB; Matteson EL; Gaylis N; Wollenhaupt J; Murphy FT; Zhou Y; Hsia EC; Doyle MK
Ann Rheum Dis; 2012 Oct; 71(10):1671-9. PubMed ID: 22459542
[TBL] [Abstract][Full Text] [Related]
19. Infliximab treatment of rheumatoid arthritis and Crohn's disease.
Nahar IK; Shojania K; Marra CA; Alamgir AH; Anis AH
Ann Pharmacother; 2003 Sep; 37(9):1256-65. PubMed ID: 12921510
[TBL] [Abstract][Full Text] [Related]
20. [Fully human anti TNF-alpha monoclonal antibodies (adalimumab, golimumab)].
Hirohata S
Nihon Rinsho; 2007 Jul; 65(7):1202-8. PubMed ID: 17642233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]